Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
about
Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme.Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDEUbiquitin is a novel substrate for human insulin-degrading enzymeA capillary electrophoresis method for evaluation of Abeta proteolysis in vitroMolecular basis for the thiol sensitivity of insulin-degrading enzymeAlzheimer's disease--a panorama glimpseIdentification of the allosteric regulatory site of insulysinMolecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme †Molecular Basis of Catalytic Chamber-assisted Unfolding and Cleavage of Human Insulin by Human Insulin-degrading EnzymeMolecular Basis for the Recognition and Cleavages of IGF-II, TGF-α, and Amylin by Human Insulin-Degrading EnzymeCrystal and Solution Structures of a Prokaryotic M16B Peptidase: an Open and Shut CaseDesigned Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of InsulinActivation of G Protein-Coupled Receptor Kinase 1 Involves Interactions between Its N-Terminal Region and Its Kinase DomainStructural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1Anion Activation Site of Insulin-degrading EnzymeConformational states and recognition of amyloidogenic peptides of human insulin-degrading enzymeImidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysisAnti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormonesMolecular Basis of Substrate Recognition and Degradation by Human Presequence ProteaseYeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.Ste24p Mediates Proteolysis of Both Isoprenylated and Non-prenylated Oligopeptides.Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screeningStructure based discovery of small molecules to regulate the activity of human insulin degrading enzymeRegulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese miceThe catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesisStepwise organization of the β-structure identifies key regions essential for the propagation and cytotoxicity of insulin amyloid fibrils.The conformational stability of nonfibrillar amyloid-β peptide oligomers critically depends on the C-terminal peptide length.Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.Cloning, expression and characterization of insulin-degrading enzyme from tomato (Solanum lycopersicum).The pyrroloquinoline quinone biosynthesis pathway revisited: a structural approach.Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1Proteomic profiling of gamma-secretase substrates and mapping of substrate requirementsA monomeric variant of insulin degrading enzyme (IDE) loses its regulatory propertiesProtective role of Cys-178 against the inactivation and oligomerization of human insulin-degrading enzyme by oxidation and nitrosylation.Neuroprotective mechanism of Kai Xin San: upregulation of hippocampal insulin-degrading enzyme protein expression and acceleration of amyloid-beta degradation.European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS).IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults.Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification.Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides.
P2860
Q24304041-6B625EE6-2728-4CF3-AB4D-045EE1D59D44Q24317274-0AC2C2DD-4FF1-4E45-BF5C-2390E7239106Q24321299-FCEBA941-9795-4AF6-A34D-4FF21BC8E11FQ24620093-94DF46AC-3185-4705-B359-587205F96B08Q24657471-2B15646D-E0C4-4504-9784-6B3C877A46FBQ27011749-3A76482C-54AE-4D0B-B1B2-AD690F4C487BQ27335211-6ECAB9A7-38EB-4108-BBB3-6E63B6B3505BQ27652766-B40CF639-5259-4FB7-AD3F-DDA69D2DB571Q27654373-97EA4C3C-5E5C-4BCF-82FF-397E015B9577Q27658095-BF01D381-7E42-4E8E-BD54-6CF96BD9DCEDQ27658164-86D147A3-B961-4169-968A-AE13F990E9A4Q27661904-672B250D-4065-4C14-A484-72C57C371557Q27666718-A6ED2592-D0CA-4A2F-AE0B-305C92B5E4BCQ27667473-A030B30D-C137-4F02-8CAC-3906146AC814Q27675355-BF62F7A2-6558-455A-BD63-9FC7414256B9Q27679412-62495F7A-E89E-4399-B419-01EB88DCA8D7Q27683399-BBBC5ABD-3EE1-41CA-A98B-D44A1EE527ADQ27683870-FCF533FC-E9A1-4B99-84C5-6C2462A3EBA5Q27684349-D94717D3-AD29-4163-9DE7-8668FFBB59BBQ27931965-E152BB5E-B57B-4287-97AD-36CCEAAD8F4AQ27935867-C71C3128-AE88-4ECC-B73E-5655BABFA67AQ28475342-070C8140-D928-4493-A708-AEC7BB1C72F4Q28480725-70D483BA-5B78-445A-80DC-AE32DA28084CQ28537971-B958440D-11A4-4FA6-B82A-C0470CB41404Q28574836-D7E841F4-56E8-4C65-AF9A-342CF305605CQ30359467-A6F44FB4-E4BE-4ECA-BD25-518883BD170CQ30574532-E5B61C68-3035-4E9A-8948-50E6E9D949FBQ33291757-8C32A0F5-CC04-4EF5-9EFB-36DE60E0A1B4Q33311567-CA449AFB-4F0B-47B1-B7AA-5F89E82E018DQ33326036-2B14BFB2-757F-4ABC-9139-EE65F775F30FQ33362745-5216E490-8DC2-40EB-8709-F05FBDE3D6A6Q33378681-28191192-E992-4B86-8590-2C0723A05858Q33543086-E039698A-B0EE-4D05-ACBB-190478525D30Q33553407-2572BBC6-2741-4B51-85A3-2382E0E645F6Q33702624-DF8890DB-6643-451C-9B13-19142DBD53CEQ33761211-C702C984-AB07-4635-9833-9B64D82DAF39Q33801010-F9580F72-0221-4D32-AB1B-A81923B53F07Q33963030-4B36A350-FB28-423E-8F4B-B45C02F64826Q34167833-09D748B5-E887-41EF-9ED0-3F7E62034E2FQ34268925-7BF589A0-0B45-48F6-B8ED-157906BFE53E
P2860
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@ast
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en-gb
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@nl
type
label
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@ast
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en-gb
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@nl
prefLabel
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@ast
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en-gb
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@nl
P2860
P921
P3181
P356
P1433
P1476
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
@en
P2093
Marsha Rich Rosner
Yuequan Shen
P2860
P2888
P3181
P356
10.1038/NATURE05143
P407
P577
2006-10-19T00:00:00Z
P5875
P6179
1029942463